Comparative Pharmacology
Head-to-head clinical analysis: PENICILLIN G POTASSIUM versus PIPRACIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENICILLIN G POTASSIUM versus PIPRACIL.
PENICILLIN G POTASSIUM vs PIPRACIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal: inhibits transpeptidases (penicillin-binding proteins) involved in bacterial cell wall synthesis, leading to cell lysis.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), interfering with peptidoglycan cross-linking during cell wall assembly.
1-4 million units IV every 4-6 hours; maximum 24 million units/day
3.375 g IV every 6 hours (piperacillin 3 g + tazobactam 0.375 g) over 30 minutes; for nosocomial pneumonia: 4.5 g IV every 6 hours over 30 minutes.
None Documented
None Documented
0.5-1 hour in normal renal function; prolonged to 3-10 hours in anuria/end-stage renal disease.
0.7-1.2 hours in adults with normal renal function; prolonged to 3-6 hours in renal impairment (CrCl <20 mL/min). In neonates, half-life is 3-4 hours.
Renal (60-90% as unchanged drug via tubular secretion and glomerular filtration); biliary (minor, <10%); fecal (minimal, <5%).
Primarily renal (tubular secretion and glomerular filtration) as unchanged drug (50-70%); biliary/fecal excretion is a minor route (approximately 10-20% as unchanged drug and metabolites).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic